JP2010047611A5 - - Google Patents

Download PDF

Info

Publication number
JP2010047611A5
JP2010047611A5 JP2009272002A JP2009272002A JP2010047611A5 JP 2010047611 A5 JP2010047611 A5 JP 2010047611A5 JP 2009272002 A JP2009272002 A JP 2009272002A JP 2009272002 A JP2009272002 A JP 2009272002A JP 2010047611 A5 JP2010047611 A5 JP 2010047611A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
angiotensin
cyclodextrin
receptor antagonist
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009272002A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010047611A (ja
Filing date
Publication date
Priority claimed from BRPI0102252-0B1A external-priority patent/BR0102252B1/pt
Application filed filed Critical
Publication of JP2010047611A publication Critical patent/JP2010047611A/ja
Publication of JP2010047611A5 publication Critical patent/JP2010047611A5/ja
Pending legal-status Critical Current

Links

JP2009272002A 2001-04-10 2009-11-30 動脈性高血圧症、他の心血管疾患、及びその合併症を治療するためのアンギオテンシンiiat1受容体拮抗薬製剤の調製 Pending JP2010047611A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0102252-0B1A BR0102252B1 (pt) 2001-04-10 2001-04-10 Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2002578949A Division JP4439814B2 (ja) 2001-04-10 2002-04-09 動脈性高血圧症、他の心血管疾患、及びその合併症を治療するためのアンギオテンシンiiat1受容体拮抗薬製剤の調製

Publications (2)

Publication Number Publication Date
JP2010047611A JP2010047611A (ja) 2010-03-04
JP2010047611A5 true JP2010047611A5 (cg-RX-API-DMAC7.html) 2011-03-03

Family

ID=3947403

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002578949A Expired - Fee Related JP4439814B2 (ja) 2001-04-10 2002-04-09 動脈性高血圧症、他の心血管疾患、及びその合併症を治療するためのアンギオテンシンiiat1受容体拮抗薬製剤の調製
JP2009272002A Pending JP2010047611A (ja) 2001-04-10 2009-11-30 動脈性高血圧症、他の心血管疾患、及びその合併症を治療するためのアンギオテンシンiiat1受容体拮抗薬製剤の調製

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2002578949A Expired - Fee Related JP4439814B2 (ja) 2001-04-10 2002-04-09 動脈性高血圧症、他の心血管疾患、及びその合併症を治療するためのアンギオテンシンiiat1受容体拮抗薬製剤の調製

Country Status (7)

Country Link
US (4) US7858597B2 (cg-RX-API-DMAC7.html)
EP (1) EP1389106A1 (cg-RX-API-DMAC7.html)
JP (2) JP4439814B2 (cg-RX-API-DMAC7.html)
CN (1) CN1523985B (cg-RX-API-DMAC7.html)
BR (1) BR0102252B1 (cg-RX-API-DMAC7.html)
CA (1) CA2444145C (cg-RX-API-DMAC7.html)
WO (1) WO2002080910A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0102252B1 (pt) * 2001-04-10 2013-10-22 Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
BRPI0105509B8 (pt) * 2001-11-05 2021-05-25 Univ Minas Gerais formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga
ES2314227T7 (es) 2002-04-09 2012-11-19 Flamel Technologies Formulacion farmaceutica oral en forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de amoxilicina.
JP4732696B2 (ja) 2002-04-09 2011-07-27 フラメル・テクノロジー 活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
WO2003093262A2 (en) 2002-04-29 2003-11-13 Teva Pharmaceutical Industries Ltd. Processes for preparing losartan and losartan potassium
KR100554156B1 (ko) * 2003-07-26 2006-02-22 학교법인 포항공과대학교 쿠커비투릴 유도체가 응집되어 형성된 나노 입자, 그 나노입자에 약물이 담지된 약제학적 조성물, 및 이들의 제조방법
HRP20031029A2 (en) * 2003-12-12 2005-08-31 Belupo - Lijekovi I Kozmetika D.D. Process for production of inclusion complexes of valsartan with?-cylodextrin
CA2598410A1 (fr) * 2005-02-21 2006-08-24 Flamel Technologies Forme pharmaceutique orale de losartan
FR2882260A1 (fr) * 2005-02-21 2006-08-25 Flamel Technologies Sa Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
FR2884145A1 (fr) * 2005-04-06 2006-10-13 Flamel Technologies Sa Forme pharmaceutique orale de losartan
WO2008052295A1 (en) * 2006-10-30 2008-05-08 Universidade Federal De Minas Gerais Process for the preparation of compounds of at1 receptor antagonists with angiotensin-(1-7), analogues thereof and/or mixtures of these systems, pharmaceutical compositions thereof and use of their derivative products
BRPI0806230A2 (pt) * 2007-01-26 2021-05-25 Universidade Federal De Minas Gerais - Ufmg composições farmacêuticas, método para tratar a disfunção erétil e método para restaurar a capacidade de ereção
CN101888829A (zh) * 2007-10-09 2010-11-17 诺瓦提斯公司 缬沙坦的药物制剂
BRPI0800585B8 (pt) 2008-02-13 2021-05-25 Univ Minas Gerais composições farmacêuticas do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7) e uso do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7)
BR102012009317B1 (pt) * 2012-04-20 2022-05-31 Universidade Federal De Minas Gerais - Ufmg Processo de preparação de compostos de inclusão envolvendo ciclodextrinas e fármacos, usando um sistema de fluxo contínuo
US10441548B2 (en) 2015-11-12 2019-10-15 Graybug Vision, Inc. Aggregating microparticles for medical therapy
MX2019011242A (es) 2017-03-23 2020-01-21 Graybug Vision Inc Farmacos y composiciones para el tratamiento de trastornos oculares.
MX2019013363A (es) 2017-05-10 2020-01-13 Graybug Vision Inc Microparticulas de liberacion extendida y suspensiones de las mismas para terapia medica.
EP4125809A1 (en) * 2020-03-25 2023-02-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Liposomal formulations comprising at1 receptor blockers and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5671073A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
JPS6025967A (ja) 1983-07-21 1985-02-08 Eisai Co Ltd トリパミド包接化合物
US4576958A (en) 1984-01-23 1986-03-18 E. I. Du Pont De Nemours And Company Antihypertensive 4,5-diaryl-1H-imidazole-2-methanol derivatives
US4666705A (en) * 1985-06-03 1987-05-19 E. R. Squibb & Sons, Inc. Controlled release formulation
US5256687A (en) 1985-09-09 1993-10-26 Hoechst Aktiengesellschaft Pharmaceutical composition for the treatment of high blood pressure
GB8613688D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
DK406686D0 (da) 1986-08-26 1986-08-26 Hans Bundgaard Carboxylsyrederivater
US5210079A (en) 1988-01-07 1993-05-11 E. I. Du Pont De Nemours And Company Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists
GB8911854D0 (en) 1989-05-23 1989-07-12 Ici Plc Heterocyclic compounds
US5064825A (en) 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
JPH03275617A (ja) * 1990-03-22 1991-12-06 Teikoku Seiyaku Co Ltd サイクロデキストリン類包接生理活性物質含有ポリ乳酸類マイクロスフェア及びその製造方法
IL100917A0 (en) * 1991-02-16 1992-11-15 Fisons Plc Pyridinone and pyrimidinone derivatives,their preparation and pharmaceutical compositions containing them
HU209658B (en) * 1992-02-21 1994-10-28 Cyclolab Kft Process for producing cyklodextrin inclusion compexes of fatty acids and their alkalimetal salts, as well as aqueous solutions of the complexes, and microbiological culture medium containing the complexes
AT399718B (de) 1992-04-16 1995-07-25 Lek Tovarna Farmacevtskih Inklusionskomplexe von optisch aktiven und racemischen 1,4-dihydropyridinen mit methyl-beta- cyclodextrin oder anderen cyclodextrinderivaten, ein verfahren zur herstellung von optisch aktiven dihydropyridinen und deren inklusionskomplexen und diese komplexe enthaltende pharmazeutische formulierungen
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5266583A (en) 1992-09-01 1993-11-30 Merck & Co., Inc. Angitotensin II antagonist
RU2128499C1 (ru) * 1992-12-23 1999-04-10 Сайтек С.Р.Л. Способ получения фармацевтических форм с контролированным высвобождением действующего вещества и формы, полученные данным способом
AU6818094A (en) * 1993-04-22 1994-11-08 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
BE1008307A3 (fr) * 1994-06-16 1996-04-02 Europharmaceuticals Sa Sel de nimesulide hydrosoluble, solution aqueuse le contenant, sa preparation et son utilisation.
US5728402A (en) 1994-11-16 1998-03-17 Andrx Pharmaceuticals Inc. Controlled release formulation of captopril or a prodrug of captopril
US5834432A (en) 1995-06-06 1998-11-10 The University Of Southern California Use of angiotensin II Type 2 receptor agonists in tissue repair
SE9502219D0 (sv) 1995-06-19 1995-06-19 Astra Ab Novel medical use
US6087386A (en) 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
WO1998018787A1 (en) 1996-10-29 1998-05-07 Merck & Co., Inc. Process for the crystallization of losartan
US5916883A (en) 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
IT1295405B1 (it) 1997-09-30 1999-05-12 Merck Sharp & Dohme Italia S P Uso di un antagonista recettoriale di angiotensina ii per la preparazione di farmaci per aumentare il tasso di sopravvivenza di
JPH11315034A (ja) * 1998-03-04 1999-11-16 Takeda Chem Ind Ltd アンギオテンシンii拮抗作用を有する化合物の徐放性製剤、その製造法および用途
ES2154191B1 (es) 1998-11-24 2001-10-16 Ferrer Int Nuevos acetales derivados de los 2-alquil-5-halo-3-(2'-(tetrazol-5-il)-bifenil-4-ilmetil)-3h-imidazol-4-carbaldehidos.
FR2787330A1 (fr) 1998-12-18 2000-06-23 Sanofi Sa Composition pharmaceutique contenant, en association, un antagoniste des recepteurs at1 de l'angiotensine ii et un immunosuppresseur pour la prevention ou le traitement des complications vasculaires du rejet de greffe
ATE487491T1 (de) 1999-02-19 2010-11-15 Takeda Pharmaceutical Präparationen zur perkutanen aufnahme von zusammnesetzungen die einen angiotensin-ii- rezeptorantagonismus aufweisen
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6178349B1 (en) 1999-04-15 2001-01-23 Medtronic, Inc. Drug delivery neural stimulation device for treatment of cardiovascular disorders
IT1307265B1 (it) 1999-08-09 2001-10-30 P F C Italiana Srl Speciality Procedimento per la preparazione di prodotti intermedi nella sintesidi lisinopril.
BR0102252B1 (pt) * 2001-04-10 2013-10-22 Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso

Similar Documents

Publication Publication Date Title
Tonglairoum et al. Fabrication of mucoadhesive chitosan coated polyvinylpyrrolidone/cyclodextrin/clotrimazole sandwich patches for oral candidiasis
DeStefano et al. Applications of PLA in modern medicine
Malikmammadov et al. PCL and PCL-based materials in biomedical applications
Popov et al. Mucus-penetrating nanoparticles made with “mucoadhesive” poly (vinyl alcohol)
JP2010511433A5 (cg-RX-API-DMAC7.html)
US10245244B2 (en) Pharmaceutical formulations for the treatment of pulmonary arterial hypertension
JP6078480B2 (ja) 移植可能な膨潤性生体吸収性ポリマー
US20090010982A1 (en) Biocompatible adherent sheet for tissue sealing
JP2011508789A5 (cg-RX-API-DMAC7.html)
JP2009542418A (ja) 埋込み型医療デバイスのための相分離したブロックコポリマーコーティング
KR102369530B1 (ko) 마이크로 니들 및 이의 제조 방법
EP2107910A2 (en) Polymer-drug conjugates with tether groups for controlled drug delivery
US20160089444A1 (en) Materials for modulating biological responses and methods of making
Patel et al. Biodegradable polymers: emerging excipients for the pharmaceutical and medical device industries
JP2011508791A5 (cg-RX-API-DMAC7.html)
Hazra et al. Polymeric composite matrix with high biobased content as pharmaceutically relevant molecular encapsulation and release platform
Shahid et al. Nanocomposite hydrogels-a promising approach towards enhanced bioavailability and controlled drug delivery
JP4439814B2 (ja) 動脈性高血圧症、他の心血管疾患、及びその合併症を治療するためのアンギオテンシンiiat1受容体拮抗薬製剤の調製
JP2008546811A5 (cg-RX-API-DMAC7.html)
JP2009545637A5 (cg-RX-API-DMAC7.html)
Kanth et al. Recent advancements and perspective of ciprofloxacin-based antimicrobial polymers
Xu et al. Advanced biomimetic materials in the prevention of tendon adhesions: design, preparation, and application of hydrogel and electrospun fiber membranes
Quiroga et al. Use of Chitosan as a Precursor for Multiple Applications in Medicinal Chemistry: Recent Significant Contributions
Niaz et al. Prospectives of antihypertensive nano-ceuticals as alternative therapeutics
WO2014041489A2 (en) Pharmaceutical dosage form